02 August 2018
Visiongain’ has launched a new pharma report Biosimilar Monoclonal Antibodies Market Report : Biosimilar Versions of Infliximab, Rituximab, Trastuzumab, Adalimumab, Bevacizumab and Abciximab
Biosimilar monoclonal antibodies (mAbs) form an emerging sector in pharmaceuticals. As patents for some of the industry’s top-selling biological drugs (biologics) expire, companies have chosen to invest in the development of biosimilars. The result is an R&D pipeline holding at least 86 biosimilar mAb candidates. Emerging markets with less stringent regulatory processes, such as India and Russia, dominated shares of the market in 2017. However, in addition to China, the more developed markets of the US and the EU5 will increase their market shares throughout the forecast period as patents expire on the originator products.
The lead analyst of the report commented “The biosimilar mAbs market will face challenges posed by competition from biobetters and a lack of confidence of some clinicians in biosimilar interchangeability. However, these challenges will be overcome owing to the high demand worldwide for affordable biological drugs, especially therapeutic monoclonal antibodies. Visiongain expects governmental policy to increase preferences for the use of biosimilars mAbs over branded ones as healthcare budgets become increasingly strained. Biosimilar mAbs will therefore have an important, rising role to play in healthcare systems from 2016 to 2028.”
Leading companies featured in the report include BIOCAD, Biocon, BioXpress, Celltrion, Coherus Biosciences, Gene Techno Science, Genor Biopharma, Harvest Moon, Hospira, Mabion, Pfizer, Samsung Bioepsis
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
21 July 2021
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
20 July 2021
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.
14 July 2021
Digital innovation in clinical trials and renewed focus on home production will ensure a high growth market for supply chain optimisation.